Cargando…
Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters discussed recent updates to clinical practice for HER2-positive m...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184838/ https://www.ncbi.nlm.nih.gov/pubmed/37197725 http://dx.doi.org/10.6004/jadpro.2023.14.3.13 |